Extracted from this filing and checked against the source text.
Executive change
SEC 8-K Item 5.02
confidence 1.0
Andrei Floroiu resigned as President, Chief Executive Officer and Member of the Board of Directors at Vaxart, Inc..
- Action
- resigned
- Role
- President, Chief Executive Officer and Member of the Board of Directors
Exact text from the filing
On January 15, 2024 (the “Separation Date”), Andrei Floroiu resigned (i) as President and Chief Executive Officer of the Company, and (ii) as a member of the Company’s Board of Directors
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 1.0
David Wheadon was appointed as Lead Director at Vaxart, Inc..
- Action
- appointed
- Role
- Lead Director
Exact text from the filing
On January 15, 2024 David Wheadon, M.D. was appointed to serve as Lead Director of the Board and will receive an annual cash retainer equal to $25,000 for such service
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 1.0
Michael J. Finney was appointed as Interim Chief Executive Officer at Vaxart, Inc..
- Action
- appointed
- Role
- Interim Chief Executive Officer
Exact text from the filing
On January 16, 2024, the Board announced that, effective as of January 16, 2024, the current Chair of the Board, Michael J. Finney, Ph.D, has been appointed as Interim Chief Executive Officer of the Company.
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
Vaxart, Inc. entered into ASPR Contract with U.S. Government through the Department of Health and Human Services, Office of the Administration for Strategic Preparedness and Response (the "ASPR") valued at $9,271,193.00 (effective 2024-01-12).
- Action
- entry
- Counterparty
- U.S. Government through the Department of Health and Human Services, Office of the Administration for Strategic Preparedness and Response (the "ASPR")
- Value
- $9,271,193.00
- Effective
- 2024-01-12
Exact text from the filing
On January 12, 2024, Vaxart, Inc. (the “Company”) was awarded a contract (the “ASPR Contract”) by the U.S. Government through the Department of Health and Human Services, Office of the Administration for Strategic Preparedness and Response (the “ASPR”). Under the ASPR Contract, the Company will receive an award to support clinical trial planning activities for a Phase 2b clinical trial that would compare the Company’s XBB vaccine candidate to an mRNA comparator to evaluate efficacy for symptomatic and asymptomatic disease, systemic and mucosal immune induction, and adverse events.
View on SEC.gov